Препараты для язвенного колита

…, ., .., .

.

 — , . , , . . . , . , , . , . : – «» , ; – , , – , , . , , , .

. «» . , 35–60% , 90% ,  — . . ? . 4% ,  — 30%. 2–3 . , , . , , .  — , , . , – , , . : 3 , .

 — , :  — 20 , ( 20 40 ) (40–80 ). 60–70% , , , . , , . . , «» . . , . , . , . , 100 . , .

, , «» – , , , «» . 50- , . , . ( 20–40 /,  — 100–250 / .) , – . , «» . 5- (5-). 5- , , . , . , 5-  — 1 4 . 287 , 5- 1, 2 4 /10/. 27% , 5- — 67, 65 75% . , 8 /. , 5-. 2 /. 90% , . , 5- 4 . – , , .

, . , . 5- , . , . , 5-. , . 1–2 , , –  — 6–8 . 2–3 . 5- , 5- . .

. 5- ? , , «» 5-. ( , , , ) – . . , 60% , 90% — . , . , «» , . 4–6 . 0,5 , 2 / ( «»). , , 1 , 2–3 . – . «» 5- (, , ). 5- – . 5- >7,  — >6,  — . , . 5-, , , . Sutherland et al. /32/ – 8 , 1000 , 5- . : ) 2,0 , OR — 1,5; 95%; CI — 0,89–2,6; ) 2,0 2,9 /, OR — 1,9; 95%; CI — 1,3–2,8; ) 3,0 , OR — 2,7; 95%; CI — 1,8–3,9. 80% 5- 2,0–4,8 /. , 5-.

, . . . «» 5- — . 5- – . , 5- .

. 400 / 120 / 5–7 , 1,0–1,5 / . 3 , . 80%. . . , , :  — ,  — , , , , . , , , . «» . 30 /, , . D. , – , , .

: 1) ; 2) ; 3) , , , .

– , . – 1 / 100 / 3- . . 10–14 . , « ». , .

, , . .  — . 10 / 3 /7/. : , , / .

. , 40 . . – , , « ». . : 1 (5 ) 10 5 6–10 . ó .

() . , 2/3 . , (9 /) 30 . .

, . 20- , 40–80% . 4 . , 3 . (2,0–2,5 /) ( 6 ). , . . ,  — 0,3% . 11,1% , 50%.

, . , . , 25 / / . . . , . 5 , . .

, , . / 5 / , 8  — . – . .

 — , . «» . , 5 ,  — 6–8  — 5-  — . . ,  — . -,  — . /1/. . , , , /8/.

5 / . – , -2 -. . 40–69% . / 2–4 / 500 / 7–10 . 5–8 / 300 /. , 5 / . 3 , , . ( , ) , , . 64% . 80 170 / – . , , .

 — . . -. , . /24, 29/. 364 , ( 5-), 5 /, 10 / . 0, 2 6 , 8 . , 60–62% 5 / 8 31–34% — (P<0,001). , 54 (46 18%). . , / /12/. , – . , . . , . , . , . , , 1 . . , , , , .

, , . , , . 2 /, «» . -, «» , (OR — 1,29; 95%; CI — 1,06–1,57) /33/. – , , /11/. -, , 5-. 2,4 / , 1,6 /, 3 , 2 /. , , /4/. . . , 5- (OR — 2,41; 95%; CI — 1,05–5,54) /19/, (OR — 2,03; 95%; CI — 1,28–3,20) /20/, ( + ) /6, 25/.  — . , . 5- 2–4 . . , 5- E.coli Nissle 1917 , 5- /15, 23/.

, . , «» . 4, , , , , .

-3 () 5- , 4. /17/. , 5–22 6 . , 25–30% /28/. , . (, , ), . 91 65% /3/. , , . , 105 5- Plantago ovata (). , /9/. , , . , , /13/. ,  — . , , /26/. , , , . -1 , 4 , 5 9 /35/. / (2 / 2–5 ,  — 200–700 / 2 3–6 ) /16/. – , . , «» . . /36/.

 — , , , /31/. , . , 20 // . 12 88% 100% — /21/.  — (FK-506) — . . , /2, 14, 18/.

. . . , 80% 33% /30/, . , 1 22,5 , 2–3  — 7,5 /27/. – 0,5 /. 12 – 60% /34/. CD3 /22/, -2 /5/. , CD25, , , , .

, , , . , , . , .. , , .

1. Ayabe T., Imai S., Ashida T. et al. Glucocorticoid receptor beta expression as a novel predictor for therapeutic efficacy of corticosteroid in patients with ulcerative colitis// Gastroenterology.-1998.-114.- A 924.

2. Bloom S., Kiilerich S., Lassen M.R. et al. Randomized trial of Tinzaperin, a low molecular weight heparin (LMWH) versus placebo in the treatment of mild to moderately active ulcerative colitis// Gastroenterology.- 2003 – 124.- 4.- Suppl. 1.- P. 540.

3. Breuer R.I., Soergel K.H., Lashner B.A. et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomized, placebo controlled trial// Gut.-1997.-40.-4.- P. 485–491.

 4. Casellas F., Vaquero E., Armengol J.R., Malagelada J.R. Practically of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis// Hepato-Gastroenterology.- 1999.- 46.- 28.- P. 2343–2346.

5. Creed T., Hearing S., Probert Ch. et al. Basiliximab (IL-2 Receptor antagonist) as a steroid sensitizing agent in steroid resistant ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 65.

6. D’Albasio G., Pacini F., Camarri E. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative proctitis: a randomized double-blind study// Am. J. Gastroenterol.- 1997.- 92.- P. 1143–1147.

7. ECCO Consensus on the Management of Crohn’s disease// Gut.- 2006.- 55 (Suppl.1).

8. Farrel R.J., Murphy A., Long A. et al. High multidrug resistance ( P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy// Gastroenterology.- 2000.- 118.- P. 279–288.

9. Fernandez-Banares F., Hinojosa J., Sanches-Lombrana J.L. et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis// Am. J. Gastroenterol.- 1999.- 94.- P. 427–433.

10. Hanauer S.B. Dose-ranging study of mesalamine (pentasa) enemas in the treatment of acute ulcerative proctosygmoiditis : Results of a multicentered placebo-controlled trial// Inflam. Bowel Dis.- 1998.- 4.- 79–83.

11. Hanauer S.B., Meyers S., Sachar D.B. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease./ In: Kirsner J.B., Shorter R.G., ed. Inflammatory bowel disease.- 4th ed.- Baltimore.- Williams and Wilkins.- 1995.- 643–663.

12. Jarnerot G., Hertervig E., Friis-Liby I. et al. Inflixomab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study// Gastroenterology.- 2005.- 128.- P. 1805–1811.

13. Kanauchi O., Mitsnyama K., Andoh A. et al. Beneficial effects of prebiotics, germinated barley foodstuff, in the long term treatment of ulcerative colitis: a multi-center open control study// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 1749.

14. Korzenik J., Miner P., Stanton D. et al. Multicenter, randomized, double-blind, placebo-controlled trial of Deligoparin (ultra low molecular weight heparin) for active ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 539.

15. Kruis W., Schutz E., Fric P. et al. Double-blind comparison of an oral Echerichia coli preparation and mesalazine in maintaining remission of ulcerative colitis// Aliment. Pharmacol. Ther.- 1997- 15.- P. 853–858.

16. Levine D.S., Fischer S.H., Christie G.L. et al. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative colitis and Crohn’s disease// Am. J. Gastroenterol.- 1992.- 87.- P. 91–100.

17. Loeschke K., Ucberschaer B., Pietsch A. et al. N-3 fatty acids retard early relapse in ulcerative colitis// Abstract. Book AGA.- 1996.- A 781.

18. Marc A., De Bievre, Anton A. et al. A randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 543.

19. Marshall J.K., Irvine E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis// Aliment. Pharmacol. Ther.- 1995.- 9.- 293–300.

20. Marshall J.K., Irvine E.J. Rectal corticosteroids vs. alternative treatment in ulcerative colitis: a meta-analysis// Gut.- 1997.- 40.- P. 775–781.

21. Orth T., Reters M., Schlaak J.F. et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study// Am. J. Gastroenterol.- 2000.- 95.- P. 1201–1207.

22. Plevy S.E., Salzberg B.A., Regueiro M. et al. A humanized anti-CD3 monoclonal antibody, Visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase 1 study// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 62.

23. Rembacken B.J., Snelling A.M., Hawkey P.M. et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial// Lancet.- 1999.- 21.- P. 635–639.

24. Rutgeerts P., Feagan B., Olson A. et al. A randomized placebo-controlled trial of infliximab therapy for ulcerative colitis: Act 1 tria.// Gastroenterology.- 2005.- 128.- A 689.

25. Safdi M., DeMicco M., Sninsky C. et al. A double blind comparison of oral vs. rectal mesalamine vs. combination therapy in the treatment of distal ulcerative colitis// Am. J. Gastroenterol.- 1997.- 92.- P. 1867–1871.

26. Saibil F.G. Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety// Gastroenterology.- 1998.- 114.- Pt 2.- P. 4395.

27. Sakuraba A., Naganuma M., Hibi T., Ishii H. Intensive therapy of granulocyte and monocyte absorption apheresis induces rapid remission in patients with ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl 1.- T. 1379.

28. Sandborn Q., Tremaine W., Offord K. et al. Transdermal nicotine for mildly to moderately active ulcerative colitis// Ann. Intern. Med.- 1997.- 126.- P. 364–371.

29. Sandborn W., Rachmilewitz D., Hanauer S. et al. Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 tria.// Gastroenterology.- 2005.- 128 (suppl.2).- A 688.

30. Sawada K., Kusugam K., Suzuki Y. et al. Multicenter randomized double blind controlled trial for ulcerative colitis therapy with leukocytapheresis// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- P. 542.

31. Skelly M.M., Curtis H., Jenkins D. et al. Toxicity of mycophenolate mofetil (MMF) in patients with inflammatory bowel disease (IBD)// Gastroenterology.- 2000.- 14.- P. 171–176.

32. Sutherland L.R., May G.R., Shaffer E.A. Sulphasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis// Ann. Intern. Med.- 1993.- 118.- P. 540–549.

33. Sutherland L., Roth D., Beck P. et al. Alternative to sulphasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis// Inflam. Bowel Dis.- 1997.- 3.- P. 665–678.

34. Tilg H., Vogelsang H., Ludwiczek O. et al. A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl .1.- P. 472.

35. Van Assche G., Noman M., Asnong K., Rutgeerts P. The use of the neurokinin-1 receptor Antagonist, SR-140333B, Nolpitantium Besilate, in mild to moderate active ulcerative colitis// Gastroenterology.- 2003.- 124.- 4.- Suppl. 1.- T 1377.

36. Wright J.P., Winter T.A., Candy S., Marks I. Sucralfate and methylprednisolone enemas in active ulcerative colitis — a prospective, single-blind study// Dig. Dis. Sci.- 1999.- 44.- 9.- P. 1899–1901.